Member Info for HedgeHogarth

What a very strange and random post by our resident troll - going by the name of one2one today and blue-bottle on other days

Treasury shares are those owned by a company

No relevance whatsoever to Hemo right now. (unfortunately) A company may take the decision to buy its own shares when it has excess cash and believes their shares are undervalued. (Wickes have been doing this and SEED are about to start too)

It is usually seen as a good thing for investors as it reduces the number of shares in the market.

But i repeat - this is a pure distraction. Hemo have NO plans to buy its own shares right now.

Jog on One2One - still amazed that LSE are still letting you post

The trolls are trying to fill the forum with FUD today so worth re-capping on where we are:

Hemogenyx are on the verge of going clinical - with Phase 1 trials of Hemo CAR-T expected to start this year!

- FDA has accepted the Company's plan to address the FDA's concerns that resulted in a Clinical Hold (RNS - 14th Sept)

- Hemo have unveiled their strategic partner - Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study

- Prevail Partners (a specialist Biotech investment fund) has agreed to invest £668k in Hemogenyx at a 240% premium. They are paying c6p a share for 11m shares.

- Prevail Partners conducted a significant amount of Due Diligence in Hemogenyx ahead of making their decision to invest

Cash / Funding

- The interim report is due out this week - I am expecting to to confirm that Hemo have a bank balance of between £4m and £5m.

- With the extra £688k injection from the Prevail deal - this will ensure Hemogenyx are fulled funded for 12-18mth and enough to comfortably complete Phase 1 trials.

- Vlad actively courting strategic investors to accelerate CBR

Clinical assets - Hemo have an enviable portfolio of propriety clinical candidates and assets

CAR-T - At Phase 1 - Targeting AML Leukaemia

CDX Bispecific Antibody - Pre Clincial - working in partnership with Selexis to take CDX into the clinic. It provides an alternative solution for better AML outcomes and for preparing a Bone Marrow Transplant

CBR - the golden ticket? Unique solution identified by Hemo that has worked wonders in the Lab on synthetic viruses. Right now, it has the potential to combat all most lethal viruses affecting humans (Covid-19, Zika, Debgue, Marburg virus.

Ebola virus and even measles. Many, many people are dying from these diseases.

CBR is also being positioned as a potential defensive weapon in Biodefense.

Right now, CBR is being tested by independent third parties on the live viruses in US Government controlled secure labs. Results are eagerly anticipated and must be due soon

Good luck everybody

Very much doubt the company will do a placing before it announces the commercial deals.

It is worth remembering that this SP is already 50% down in the last 3 months.

The company have been very transparent with their cash position

So worth reading this line again:

"additional sums receivable from key customers and JV partners"

in conjunction with

"immediate revenue generating opportunities in the rapidly expanding global lightweight electric vehicle (EV) sector with a particular focus on India and Asia"

These are in high demand and given I'm sure upfront payments will be a key part of the commercial deals

GLA - great entry point today as expected

And there is a big gap just below 3p...

Directors dealing (which is what it would be if Vlad exercised his options) would need to be communicated within 3 days

There is NO way in the world Vlad has exercised them yet.

Tranche 1 (c 23m options at a 2.5p price) - these have vested (i.e They are Vlad's to keep) and have a 5 year expiry date. He will be waiting til the SP is much higher than today or more likely at a point at which Hemo are bought. If he exercised them last week he would have had to cough up £550k

I imagine we will get an RNS very soon to say that Tranche 2 (35m options) has vested - they vest when FDA gives the OK to start clinical trials. These will have a exercise price of 2.875p.

Vlad is effectively being rewarded with the opportunity at any point in the next 5 years to acquire up to c5% of the company at todays very low prices.

So, if and when, share price is in double figures following Ph1 results of CAR-T of a big commercial deal on CDX or CBR he'll be handsomeley rewarded.

If, on the other hand, the SP stays at current levels, he will probably never exercise them.

I think we ALL know which is more likely.

GLA

Well he got Hemo bang on earlier on the well.👍

2 tremendous RNS :-)

SP re-rate back in line with Placing Price of 2.5p

Closing SP Today of 2.45p - I'm not chartist or trader but Zak Mir is - He said he expects it to fill the gap to 3p with the upside valid with a close above the previous resistance level of 2.4p Infact, we are sitting at the SP reached before the clinical hold was announced.

Looking at the trend, it is nice to see the share hold its significant gain of c60-70%

Date Open High Low Close Volume

Sep 22, 2023 2.58p 2.65p 2.40p 2.45p 7,121,745

Sep 21, 2023 2.60p 2.70p 2.50p 2.58p 7,930,351

Sep 20, 2023 2.45p 2.70p 2.30p 2.60p 10,928,303

Sep 19, 2023 2.63p 2.80p 2.40p 2.45p 32,522,291

Sep 18, 2023 2.20p 2.79p 2.10p 2.55p 48,596,987

Sep 15, 2023 1.75p 1.90p 1.75p 1.85p 5,733,632

Sep 14, 2023 1.85p 1.95p 1.61p 1.75p 21,742,959

Sep 13, 2023 1.70p 1.72p 1.61p 1.65p 2,992,167

Sep 12, 2023 1.70p 1.75p 1.65p 1.70p 1,343,438

Sep 11, 2023 2.00p 2.00p 1.65p 1.70p 10,162,819

Sep 8, 2023 1.48p 2.05p 1.45p 1.93p 19,983,666

I see that joker or a troll is back - cannot believe they are still allowed to post are revealing that he or she posts on multiple aliases to spread his FUD.

Nobody here thinks £680k will take CAR-T through the clinical trials process. The process will take tens of millions over 3-5 years.

What we do believe is that the £680k on top of the £4-5m that Hemo have in the bank will fund them for 12-18mth which will see them comfortably through Phase 1 trials and towards Phase 1b or 2.

Let's remember that one of Hemo's outstanding qualities is to avoid burning too much cash. Taken from their most recent annual report "thank our CEO Dr Vladislav Sandler and his scientific team for their excellent and highly productive work under a tight budget"

Back in your box one2one / blue-bottle - very apt that you chose a dirty vermin for your double alias.

Pumpky - positive results do move the SP. But when released many will be the big rise.

To benefit from the rise, research into what might be in store for Hemo when they start trials, chances of success and likely impact on valuation if results are good is invaluable. Gets me ahead of the curve

LTHers are not making this stuff up - it's all there to see with the right research :-)

I don't always agree with Mr India - but he is right, it's just a waiting game now

Hemo are on the cusp of achieveing the very difficult PreClincial stage

And about to enter Ph 1 where more drugs / therapies are successful (60-80% success rate)

GLA

Or...

Company valuation ($ millions) Mean 95% CI

Pre-Clinic 88 (57–119) (HEMO ARE HERE)

Phase 1 399 (211–498)

Phase 2 734 (436–930)

Phase 3 1656 (996–2527)

Approved 2496 (1582–3355)

Success rate (%)

Pre-Clinic to Phase 1 32.0 (28.8–35.2) (HEMO, AGAINST THE ODDS (just 32%) about to mature to Phase 1)

Phase 1 to Phase 2 75.8 (68.2–83.4)

Phase 2 to Phase 3 55.6 (50.0–61.2)

Phase 3 to Approved 67.7 (60.9–74.5)

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854317/

Avg Valuations - by clinical phase

On average, companies with lead products in pre-clinical development were acquired for a total transaction value of $88 million (95% CI $56–120 million). Mean valuations rose to $354 million (95% CI $211–498 million) for Phase 1, $683 million (95% CI $436–930 million) for Phase 2, $1761 million (95% CI $996–2527 million) for Phase 3, and $2469 million (95% CI $1582–3355 million) for Approved lead products. However, the acquisition value displayed a high dispersion within development stages. Therefore, only the transitions from Pre-Clinic to Phase 1 (p 

Davie_b

£100-£200m mCAP is realistic with the following sequence of events in my view

- Commence Ph 1 trials of CAR-T (Last RNS stated the expectation is these will commence in FY23)

- Indication of good results in Ph 1 - Prevail will be providing Hemo with realtime updates and will start to see results very quickly. Because of the nature of the target (relapsed/refractory AML) we are likely to get both an indication of the safety and the efficacy. Good news on both is a BIG catalyst for the SP - even just good news on safety will be great news as Ph 1 trials are used to tweak dosage and other factors to maximise efficacy and safety. There is a greater than 50% chance of CAR-T being successful in Ph 1 trials. I'm hoping the odds are better than that given the advanced humanised mice that Hemo have used to develop it

Following or ahead of the above the following would also be help increase the value of the company:

- An update on CDX - we are in partnership with Selexis to take a biospecific antibody solution for AML into clinical trials

- An update on CBR - there was a blockbuster update in January that put 200% on the vale of the company. A further update is expected soon on how its progressing against live viruses and in animals

- Further funding / partnerships solutions that are not wholly dilutionary for shareholders

- and a new website would be nice!

There are numerous articles online that discuss the pivotal change in value when a drug or therapy shows promise in Ph1 trials. Even just starting clincial trials is a key milestone for small Biotech companies

DYOR and believe me, I've not been here for 4 years for a 10p share price!!! My aspirations are far higher

Sorry! Could not resist covchump - i knew someone would call me out :-)

JHFH (Just Here for Hemo) should now be known as RHFH (Rarely Here for Hemo)

I can confirm that JHFH is very much alive and kicking, a great guy and very knowledgeable about Hemo

I consider myself very fortunate to be in regular contact - occasional calls, and daily messages. With much in common, steadfast belief in Hemo and both significantly invested, it's nice to have someone to chat to throughout the ups and downs

He have posted on here a reasonable amount in the last week as the forum - but he (and I and other LTHers) tend to avoid this forum when it gets occasionally overrun by trolls who post all sorts of garbage to create FUD and manipulative the narrative to suit their trading agenda.

But with so much good news delivered by Hemo in the last 2 weeks, so much more news to come and everything in place for a good year - this share is probably no longer the target of those looking to short or attempt to drive the price down

GLA

Laughable attempts to create FUD today - RobSaunders winning suggesting a raise at 0.5p! What a clown

The whole update today was about preserving cash and the likely intent to dispose an asset to raise cash. Hardly creating a need to raise

Keep going tradres - you must be able to be Rob;s effort

MCap is a mere £8-£9m at this share price

An unexpected gift today - I imagine a few mates of the BOD will be feasting on these today as well.

The RNS did not deserve a 30% drop. The SP had already taken a beating before this RNS.

It's always the honest private investors who lose out on days like this.

Look at some of those sells at 0.6p :-(

Methinks there will be a few regrets by the end of the day and many more in the coming weeks.

Competition time for pesky traders - who can post the most alarming and manipulative FUD about JAY

Whilst others just smile and top-up :-)

Board full of traders this morning trying to exacerbate the dip and sell off to get in cheaper....

For those who were well researched - today's news is not unexpected. Whilst disappointing, with hindsight, it was already priced in effectively

Better ROI on other assets

GLA - IMO, great opportunity to get in cheap today